Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study-Reference-Cited by-同舟云学术

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study

Published:2018-07-03 Issue:3 Volume:64 Page:689-707
ISSN:1387-2877
Container-title:Journal of Alzheimer's Disease
language:
Short-container-title:JAD

Author:

Salloway Stephen P.¹,Sperling Reisa²,Fox Nick C.³,Sabbagh Marwan N.⁴,Honig Lawrence S.⁵,Porsteinsson Anton P.⁶,Rofael Hany⁷,Ketter Nzeera⁷,Wang Daniel⁷,Liu Enchi⁷,Carr Stephen⁷,Black Ronald S.⁸,Brashear H. Robert⁹

Affiliation:

1. Brown Medical School, Butler Hospital, Providence, RI, USA

2. Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, MA, USA

3. Dementia Research Centre, University College London, Institute of Neurology, London, UK

4. Barrow Neurological Institute, Phoenix, AZ, USA

5. Columbia University, New York, NY, USA

6. University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

7. Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA

8. Pfizer Inc, Collegeville, PA, USA

9. Janssen Research & Development LLC, Pennington, NJ, USA

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference26 articles.

1. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease;Bard;Nat Med,2000

2. Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-beta peptide in a helical conformation;Miles;Sci Rep,2013

3. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease;Salloway;N Engl J Med,2014

4. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials;Vandenberghe;Alzheimers Res Ther,2016

5. Bapineuzumab for mild to moderate Alzheimer’s disease: A meta-analysis of randomized controlled trials;Abushouk;BMC Neurol,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ABTrans: A Transformer-based model for predicting interaction between anti-Aß antibodies and peptides;2023-10-11

2. Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease;Neurology and Therapy;2023-02-15

3. Advances in Alzheimer’s disease’s pharmacological treatment;Frontiers in Pharmacology;2023-01-26

4. Gender differences contribute to variability of serum lipid biomarkers for Alzheimer's disease;Biomarkers in Medicine;2022-10

5. Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease;CNS Drugs;2022-03-30